All In Biotech

Drug Trial Radar · NCT02565914

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

Last checked: Nov 19, 2026Latest source record: Sep 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,131

Actual

Start

Aug 2015

Primary completion

May 2019

Study completion Dec 5, 2022

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
First posted
Oct 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multicenter, open-label, 3-part rollover study in subjects with CF who are homozygous or heterozygous for the F508del-CFTR mutation and who participated in studies VX13-661-103 (Study 103, NCT02070744), VX14-661-106 (Study 106, NCT02347657), VX14-661-107 (Study 107, NCT02516410), VX14-661-108 (Study 108, NCT02392234), VX14-661-109 (Study 109, NCT02412111), VX14-661-111 (Study 111, NCT02508207), VX15-661-112 (NCT02730208), and VX16-661-114 (NCT03150719). The study is designed to evaluate the safety and efficacy of long-term treatment of VX-661 in combination with ivacaftor.

Conditions

  • Cystic Fibrosis

Interventions

  • TEZ/IVADrug

    Fixed dose tablet for oral administration.

  • IVADrug

    Tablet for oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Week 100
  2. Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEsTime frame: Day 1 up to Week 100
  3. Part C: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Week 196

Locations

154 sites in 16 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Tucson, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Oakland, California

  • Site not named

    Palo Alto, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    Gainesville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Pensacola, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Boise, Idaho

  • Site not named

    Chicago, Illinois

  • Site not named

    Glenview, Illinois

  • Site not named

    Niles, Illinois

  • Site not named

    Peoria, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Iowa City, Iowa

  • Site not named

    Lexington, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Lebanon, New Hampshire

  • Site not named

    Long Branch, New Jersey

  • Site not named

    New Brunswick, New Jersey

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Albany, New York

  • Site not named

    Buffalo, New York

Showing 40 of 154 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.